Puma Biotechnology reported a net loss of $44.7 million for Q3 2021, compared to a net loss of $31.5 million for Q3 2020. Total revenue for Q3 2021 was $46.2 million, a decrease from $50.8 million in Q3 2020. The results were negatively impacted by COVID-19 and inventory reduction.
Product revenue, net for the third quarter of 2021 was $43.4 million, compared to $49.3 million for the third quarter of 2020.
Net loss for the third quarter of 2021 was $44.7 million, or $1.09 per share, compared to a net loss of $31.5 million, or $0.79 per share, for the third quarter of 2020.
Net cash provided by operating activities for the third quarter of 2021 was $10.5 million, compared to $1.7 million for the third quarter of 2020.
The company anticipates key milestones over the next 12 months, including reporting top line data from the randomized cohort of the Phase II SUMMIT trial and data from the Phase II INSIGhT trial.
Puma Biotechnology anticipates several key milestones over the next 12 months.
Visualization of income flow from segment revenue to net income
Analyze how earnings announcements historically affect stock price performance